Room-temperature limits belong to a specific product, device, and preparation state. This guide brings the current U.S. label rules together and shows what to record after a temperature excursion.
There is no single safe room-temperature window for peptides. It depends on the exact drug, device, preparation state, highest temperature reached, and product label. FDA-approved products can have different 21-, 28-, 30-, or 56-day limits. Compounded, reconstituted, and research-labeled products cannot automatically use those same limits.
Each limit belongs to a specific device, use state, temperature ceiling, and discard rule. Use the number only with the conditions listed in its row.
Choose the brand, device, and use state printed on the label. The lookup shows storage instructions only and makes no determination about potency, sterility, or usability.
Match the brand, device, and whether it is unopened, opened, or already in use.
Read across one row only. Returning a product to the refrigerator does not erase a cumulative clock when the label says “total” days.
| Product and form | Room-temperature rule | Refrigerated rule | Discard and source |
|---|---|---|---|
| OzempicSingle-patient-use pen with multiple weekly dosesAfter first use | 56 days May be stored for 56 days at 59°F to 86°F (15°C to 30°C), or refrigerated during that period. | Before first use, refrigerate at 36°F to 46°F (2°C to 8°C). | Dispose of the pen after 56 days, even if medicine remains. May 2026 label · Section 16, single-patient-use pens |
| OzempicSingle-dose prefilled syringeBefore use | 28 days If needed, may be kept at 46°F to 86°F (8°C to 30°C) for up to 28 days. | Refrigerate at 36°F to 46°F (2°C to 8°C). | Discard the syringe after use. May 2026 label · Section 16, single-dose prefilled syringes |
| WegovySingle-dose injection penBefore cap removal | 28 days If needed, may be kept at 46°F to 86°F (8°C to 30°C) for up to 28 days before the cap is removed. | Refrigerate at 36°F to 46°F (2°C to 8°C). | Discard if frozen, exposed to light or above 86°F (30°C), or out of the refrigerator for 28 days or longer. February 2026 label · Section 16, Wegovy single-dose pen |
| MounjaroSingle-dose pen or single-dose vialBefore use | 21 days May be stored unrefrigerated at no more than 86°F (30°C) for up to a total of 21 days. | Refrigerate at 36°F to 46°F (2°C to 8°C). | Discard after a total of 21 days at room temperature. April 2026 label · Section 16.2, single-dose pen and single-dose vial |
| MounjaroMulti-dose vial or single-patient-use KwikPenUnopened or in use | 30 days At no more than 86°F (30°C), discard an unopened device after 30 days. An opened device may be refrigerated or kept at room temperature. | An unopened device may remain refrigerated at 36°F to 46°F (2°C to 8°C) until the label expiration date. | After opening, discard after 30 total room-temperature days, 30 days after first use, or 4 weekly doses, even if medicine remains. April 2026 label · Section 16.2, multi-dose vial and KwikPen |
| ZepboundSingle-dose pen or single-dose vialBefore use | 21 days May be stored unrefrigerated at no more than 86°F (30°C) for up to a total of 21 days. | Refrigerate at 36°F to 46°F (2°C to 8°C). | Discard after a total of 21 days at room temperature. April 2026 label · Section 16.2, single-dose pen and single-dose vial |
| ZepboundMulti-dose vial or single-patient-use KwikPenUnopened or in use | 30 days At no more than 86°F (30°C), discard an unopened device after 30 days. An opened device may be refrigerated or kept at room temperature. | An unopened device may remain refrigerated at 36°F to 46°F (2°C to 8°C) until the label expiration date. | After opening, discard after 30 total room-temperature days, 30 days after first use, or 4 weekly doses, even if medicine remains. April 2026 label · Section 16.2, multi-dose vial and KwikPen |
Coverage is limited to the forms and current U.S. labels listed here. Check the product label for other formulations, countries, and future revisions.
A compounded preparation has its own storage instructions. Its dispensing label, beyond-use date, formulation, container, and pharmacy instructions control. Do not transfer a branded product's 21-, 28-, 30-, or 56-day rule to it.
What to doKeep it aside and ask the dispensing pharmacist what to do with the exact product and temperature history.
A mixed vial or dry powder needs product-specific instructions. Preparation state, diluent, sterility, formulation, container, and stability evidence can all change the storage window.
What to doFollow the product instructions and beyond-use date. Contact the pharmacist or manufacturer if either is missing or a temperature excursion occurred.
A research-use label does not provide FDA-approved human-use storage instructions. Retatrutide and BPC-157 have no approved U.S. human product label with a storage window for self-use.
What to doThere is no approved U.S. human-use product label to consult for a storage window.
Pharmacists and manufacturers need the product name, time, temperature, and storage history. Appearance alone cannot establish potency, sterility, or safety.
Record the brand or pharmacy, ingredient, device or vial type, concentration, and whether it is unopened, opened, or reconstituted.
Write down when refrigeration stopped, when it resumed, the highest known temperature, and any freezing, sunlight, shipping, or power-loss event.
Use the current package insert for an approved product or the dispensing label and beyond-use date for a compounded preparation.
Set the product aside and contact the pharmacist or manufacturer. Appearance alone cannot establish a new expiration window.
FDA recommends not using injectable GLP-1 drugs that arrive warm or with insufficient refrigeration because product quality can be affected. Keep the packaging and contact the dispensing pharmacy or manufacturer.
Read the FDA warningKeep medication accessible in carry-on luggage and in its original labeled container when possible. Confirm current TSA, carrier, customs, and destination rules. Prevent freezing and direct contact with cooling elements unless the product instructions explicitly allow it.
The answers below use current U.S. labels and FDA guidance.
There is no single safe room-temperature window for peptides. It depends on the exact drug, device, preparation state, highest temperature reached, and product label. FDA-approved products can have different 21-, 28-, 30-, or 56-day limits. Compounded, reconstituted, and research-labeled products cannot automatically use those same limits.
The branded product and device determine the limit. Current U.S. labels give an in-use Ozempic multi-dose pen 56 days at 59°F to 86°F, an Ozempic single-dose syringe up to 28 days at 46°F to 86°F, and a Wegovy single-dose pen up to 28 days at 46°F to 86°F before cap removal. Compounded semaglutide follows its pharmacy label and beyond-use date.
Current U.S. Mounjaro and Zepbound labels give single-dose pens or vials up to a total of 21 days at no more than 86°F. Their multi-dose vials and single-patient-use KwikPens use separate 30-day rules, including clocks tied to first use and four weekly doses. Compounded tirzepatide needs its own pharmacy label and beyond-use date.
A compounded preparation needs its own storage instructions because its formulation, concentration, container, sterility controls, and beyond-use date can differ. Follow the dispensing label and ask the dispensing pharmacist about the temperature excursion. Do not copy a branded product's storage window.
The storage window depends on the product, diluent, concentration, preparation method, container, sterility conditions, and beyond-use date. No single room-temperature limit applies to every reconstituted peptide. Follow the product instructions and ask the dispensing pharmacist or manufacturer when the temperature history falls outside them.
Keep the package, label, and temperature history and contact the dispensing pharmacy or manufacturer. FDA recommends that patients not use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration because product quality can be affected.
Plan to keep medication and medically necessary cooling supplies accessible in carry-on luggage, in the original labeled container when possible. Check current TSA, airline, and destination-country rules before each trip, and prevent direct contact with ice or cooling elements unless the product instructions specifically allow it.
Source checked August 2, 2026. Labels change; verify the current version linked here and the label in front of you.
Save label notes, arrival dates, preparation dates, reminders, and questions in one place. Keep using the product label and professional guidance for storage and use decisions.
